- Home
- DOCS vs BMRN Comparison
DOCS vs BMRN Comparison
Compare DOCS & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DOCS | BMRN |
|---|---|---|
| Founded | 2010 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.3B | 10.5B |
| IPO Year | 2021 | 1999 |
Fundamental Metrics
Financial Performance| Metric | DOCS | BMRN |
|---|---|---|
| Price | $46.10 | $53.19 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 20 | 19 |
| Target Price | $68.05 | ★ $88.42 |
| AVG Volume (30 Days) | 2.7M | ★ 3.0M |
| Earning Date | 11-06-2025 | 10-27-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 42.88 | ★ 59.53 |
| EPS | 1.25 | ★ 2.68 |
| Revenue | $621,329,000.00 | ★ $3,094,001,000.00 |
| Revenue This Year | $15.22 | $13.39 |
| Revenue Next Year | $11.03 | $7.57 |
| P/E Ratio | $36.78 | ★ $19.92 |
| Revenue Growth | ★ 20.21 | 12.39 |
| 52 Week Low | $45.29 | $50.76 |
| 52 Week High | $85.21 | $73.51 |
Technical Indicators
Market Signals| Indicator | DOCS | BMRN |
|---|---|---|
| Relative Strength Index (RSI) | 28.80 | 46.19 |
| Support Level | $50.10 | $53.03 |
| Resistance Level | $51.80 | $54.66 |
| Average True Range (ATR) | 2.18 | 1.45 |
| MACD | 0.49 | -0.11 |
| Stochastic Oscillator | 9.53 | 31.61 |
Price Performance
Historical ComparisonAbout DOCS Doximity Inc.
Doximity Inc is a digital platform for U.S. medical professionals. The cloud-based platform provides members with tools specifically built for medical professionals, enabling them to collaborate with their colleagues, securely coordinate patient care, conduct virtual patient visits, stay up-to-date with the latest medical news and research, and manage their careers and on-call schedules.
About BMRN BioMarin Pharmaceutical Inc.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.